ストックスクリーナーアプリを入手
1.30
11.11%
0.13
Inhibikase Therapeutics Inc (IKT) 最新ニュース
Fennec Pharmaceuticals (NASDAQ:FENC) & Inhibikase Therapeutics (NYSE:IKT) Head to Head Review - Defense World
Ieq Capital LLC Purchases 2,616 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat
Just the Facts: Imugene receives Orphan Drug Designation for VAXINIA from FDA - Proactive Investors Australia
J.W. Cole Advisors Inc. Has $225,000 Holdings in InvenTrust Properties Corp. (NYSE:IVT) - Defense World
Inogen (NASDAQ:INGN) Is In A Strong Position To Grow Its Business - Yahoo Finance
Innovative Industrial Properties (NYSE:IIPR) Hits New 1-Year High at $137.91 - MarketBeat
Had You Purchased Incyte in 2004, Here’s Your Result - MMJ Stock Watch
INVX underperforms with a -2.86 decrease in share price - US Post News
Ratios Uncovered: Breaking Down Ironwood Pharmaceuticals Inc (IRWD)’s Trailing Twelve Months Metrics - The Dwinnex
Incyte Corp. (INCY) looking to reclaim success with recent performance - SETE News
InvenTrust Properties Corp. (NYSE:IVT) Short Interest Down 5.5% in August - Defense World
Get in on Invesco Ltd’s (IVZ) buy-in window today! - SETE News
The Escalator: Imre, Kyverna Therapeutics, The Bloc and more - MM+M Online
InnovAge (NASDAQ:INNV) Trading Up 4.2% - Defense World
Imugene (ASX:IMU) achieves FDA Orphan Drug Designation for VAXINIA - Kalkine Media
Incyte stock downgraded amid looming patent cliff concerns By Investing.com - Investing.com Canada
Insider Selling: InnovAge Holding Corp. (NASDAQ:INNV) Insider Sells 4,372 Shares of Stock - Defense World
InnovAge holding corp. executive sells over $70k in stock By Investing.com - Investing.com UK
Incyte DowngradedAnalyst Notes Intense Competition, Particularly In Larger Markets - Yahoo Finance
Incyte (NASDAQ:INCY) Stock Price Down 1.9% - MarketBeat
Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
Victory Capital Management Inc. Buys 52,523 Shares of Innoviva, Inc. (NASDAQ:INVA) - Defense World
Incyte (NASDAQ:INCY) Receives Market Perform Rating from JMP Securities - Defense World
Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World
Imugene gets crucial FDA nod for bile tract cancer drug - The West Australian
Imugene secures FDA orphan drug designation for bile tract cancer treatment By Proactive Investors - Investing.com Australia
Imugene Gains FDA Orphan Status for Cancer Therapy - TipRanks
Ratio Review: Analyzing Innovex International Inc. (INVX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What was Ironwood Pharmaceuticals Inc (IRWD)’s performance in the last session? - US Post News
Victory Capital Management Inc. Sells 273,806 Shares of Ingredion Incorporated (NYSE:INGR) - Defense World
Ironwood Pharmaceuticals Inc (IRWD) Becoming More Attractive for Investors - Knox Daily
Investing in Incyte Corp. (INCY): What You Must Know - Knox Daily
Incyte closes 5% higher bolstered by Zynyz data, Guggenheim note - MSN
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Illinois Tool Works Inc. stock outperforms competitors on strong trading day - MarketWatch
Healthy Upside Potential: Ironwood Pharmaceuticals Inc (IRWD) - SETE News
Should Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Investors Be Concerned? - Stocks Register
Instil Bio price target raised to $120 from $40 at H.C. Wainwright - TipRanks
Forsta AP Fonden Sells 13,900 Shares of Incyte Co. (NASDAQ:INCY) - Defense World
Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Illinois Tool Works (NYSE:ITW) Lifted to Buy at StockNews.com - Defense World
What Is Illinois Tool Works Inc.'s (NYSE:ITW) Share Price Doing? - Simply Wall St
Rathbones Group PLC Increases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat
Incyte’s Retifanlimab (Zynyz ® ) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium - NTB Kommunikasjon
StockNews.com Upgrades Illinois Tool Works (NYSE:ITW) to Buy - MarketBeat
IKT (Inhibikase Therapeutics) Operating Cash Flow per Share : $-2.81 (TTM As of Mar. 2024) - GuruFocus.com
IKT (Inhibikase Therapeutics) Cash Flow from Operations : $-15.98 Mil (TTM As of Mar. 2024) - GuruFocus.com
IKT (Inhibikase Therapeutics) Cyclically Adjusted Book per Share : $0.00 (As of Mar. 2024) - GuruFocus.com
IKT (Inhibikase Therapeutics) 50-Day SMA : $1.41 (As of Aug. 18, 2024) - GuruFocus.com
IKT (Inhibikase Therapeutics) Book Value per Share : $1.05 (As of Mar. 2024) - GuruFocus.com
IKT (Inhibikase Therapeutics) Momentum Rank : 4 (As of Aug. 17, 2024) - GuruFocus.com
Inhibikase Therapeutics Inc (IKT) Q2 2024 Earnings Call Transcri - GuruFocus.com
Inhibikase shares target cut, analyst retains buy rating on earnings report - Investing.com
Inhibikase Therapeutics (NYSE:IKT) Given New $15.00 Price Target at HC Wainwright - Defense World
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Inhibikase Therapeutics reports Q2 financials, trial updates - Investing.com
Earnings call: Inhibikase Therapeutics reports Q2 financials, trial updates - Investing.com India
Earnings call: Inhibikase Therapeutics reports Q2 financials, trial updates By Investing.com - Investing.com UK
IKT (Inhibikase Therapeutics) 14-Day RSI : 41.91 (As of Aug. 18, 2024) - GuruFocus.com
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024 - MSN
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity - GlobeNewswire
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity - Yahoo Finance
Inhibikase Therapeutics (IKT) to Release Earnings on Wednesday - Defense World
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 - GlobeNewswire
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 - Quantisnow
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 - StockTitan
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 - Yahoo Finance
Inhibikase Therapeutics gains shareholder nod for stock warrants - Investing.com
Inhibikase Therapeutics gains shareholder nod for stock warrants By Investing.com - Investing.com UK
Inhibikase Therapeutics’ $4 Million Common Stock Offering - Global Legal Chronicle
ZIVO Bioscience (NASDAQ:ZIVO) and Inhibikase Therapeutics (NYSE:IKT) Critical Contrast - Defense World
Inhibikase Therapeutics (NYSE:IKT) Shares Down 0.3% - Defense World
Inhibikase Therapeutics (NYSE:IKT) Trading Down 4.9% - Defense World
Market Resilience: Inhibikase Therapeutics Inc (IKT) Finishes Weak at 1.15, Down -4.96 – DWinneX - The Dwinnex
0.05%
4.86%
大文字化:
|
ボリューム (24 時間):